Diadema Farmaceutici
Driving Innovations in Therapeutics Driven by Robust R&D

Abottomless purse of wealth and a long-standing brand name have been the hallmarks of a successful pharmaceutical company for years. Diadema Farmaceutici (Diadema) is changing this status quo with its highly experienced team of leaders and deep understanding of the scientific market.

Within three years of commercial product launch, the company has earned a reputation for bringing innovative products to market in reasonable timelines that address the needs of physicians and patients. A young and ambitious company, Diadema is an SME founded by a group of passionate individuals with years of experience in pharmaceutical and other industries.

“Our aim is to create an image of Diadema as an innovative company focused on R&D, bringing new products to market that address critical needs,” says Giammario Piras, senior VP. “The experience and track record of our management team is what makes Diadema closely linked to the market and the requirements of patients and doctors.”

The path to success has been paved by the company’s bi-directional approach—extensive R&D and commercial launch of products. Partnerships with experienced Italian R&D companies, research centres, universities and start-ups with novel ideas enable it to introduce numerous lines of products that offer unmatched benefits.

For instance, its range of patented natural essential oil extract products has shown great results in treatments against bacteria, viruses and microorganisms that can cause dysbiosis in the human body. These extracts also showed anti-inflammatory and antioxidant properties.

Diadema went the extra mile to demonstrate safety and efficacy of the product, performing a wide-ranging surveillance study. On the product Eurekol, the company reached out to speciality doctors and general practitioners to collect surveillance data on 1,700 patients. The results were beyond satisfactory and underlined the specificity and uniqueness of the treatment, driving product sales.

This dedication to R&D today allows Diadema to create a vast product portfolio that will significantly grow in the future, thanks to new agreements and acquisitions, useful across various therapeutic areas, including ophthalmology, gastroenterology, neurology, gynaecology and regenerative medicine. With a strong foundation in R&D, the company has built a sharp and well-positioned sales team focused on face-to-face interactions with doctors to present the product’s utility.

A distinct sales model, backed by scientific knowledge and clinical studies, where medical representatives demonstrate current and future needs addressed by its products, has spearheaded Diadema to success. In 2023, the company sold over 110,000 box units and has already crossed the figure for 2024, with a potential to achieve three or four times more sales than the previous year.

Its representatives understand that doctors are always focused on the present and seek medicines that can treat current illnesses faced by patients. Diadema addresses this by leveraging the expertise of professors from its partner universities, specializing in different therapeutic areas. Their understanding of the market helps identify medical areas with greater needs for new medicines and invest in R&D to address the same.

Aiming to sustain its growth, Diadema has numerous products in the pipeline and is expanding its footprint to international markets. It has acquired majority stake in a pharmaceutical company in the Dominican Republic, which will act as an importer and distributor of its products in the region. Cross country agreements enable the company to export to eight countries. Plans are underway to establish its presence in Middle Eastern and Far East Asian countries, like China and Vietnam.

At its core is a mission to innovate by creating therapeutic solutions that increase efficacy, safety and ease of use in contrast to the current availabilities in pharmaceutical formularies. With deep roots in R&D, Diadema is on course to satisfy the most demanding therapeutic needs of doctors and enhance the care experience and well-being of patients.